William Wilcox
Expertise in
26
conditions

Dr. William Wilcox

Medical Genetics
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 
38 Years of Experience
Expertise in
26
conditions
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 

Overview

William Wilcox is a Medical Genetics provider in Atlanta, Georgia. Dr. Wilcox has been practicing medicine for over 38 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Fabry Disease, Achondroplasia, Mucopolysaccharidoses (MPS), and Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome).

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

UCLA, 1988.0

Residency

UCLA

Specialties

Medical Genetics

Licenses

Clinical Genetics in GA

Board Certifications

American Board Of Medical Genetics And Genomics, 1996

Fellowships

UCLA Intercampus Medical Genetics Training Program

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Emory Clinic at 1365 Clifton Road
1365 Clifton Road Northeast, BldgB, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Biological
Study Drug: ST-920
Study Phase: Phase 1/Phase 2
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
Enrollment Status: Available
Publish Date: August 16, 2024
Intervention Type: Drug
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Biological
Study Drug: 4D-310
Study Phase: Phase 1/Phase 2
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: AGT-181
Study Phase: Phase 1
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Biological
Study Drug: SB-318
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

62 Total Publications

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.
Journal: Orphanet journal of rare diseases
Published: November 12, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Jaime E. Vengoechea-Barrios
Medical Genetics | Pediatrics
Expertise in
9
conditions
Dr. Jaime E. Vengoechea-Barrios
Medical Genetics | Pediatrics

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (0.1 miles away)
404-778-7525
Languages Spoken:
English, Arabic, Italian, Portuguese, Spanish
See accepted insurances
Accepting New Patients

Jaime Vengoechea-Barrios is a Medical Genetics specialist and a Pediatrics provider in Atlanta, Georgia. Dr. Vengoechea-Barrios is highly rated in 9 conditions, according to our data. His top areas of expertise are Megalencephalic Leukoencephalopathy with Subcortical Cysts, Multiple Sulfatase Deficiency, Fabry Disease, and Gaucher Disease Type 3. Dr. Vengoechea-Barrios is currently accepting new patients.

Hisa Yamaguchi
Expertise in
22
conditions
Dr. Hisa Yamaguchi
General Surgery | Medical Genetics
Expertise in
22
conditions
Dr. Hisa Yamaguchi
General Surgery | Medical Genetics

Piedmont Physicians Surgical Specialists Eastside

1700 Tree LN, Ste 450, 
Snellville, GA 
 (18.0 miles away)
770-972-7999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hisa Yamaguchi, MD is board certified by the American Board of Surgery and is a member of the American Society of Breast Surgeons. Dr. Yamaguchi has practiced in the Gwinnett county area since 1995. Although she performs general surgery, Dr. Yamaguchi's heart and passion is devoted to breast disease and breast cancer surgeries. She is known for her compassion and positive impact with patients so much that they have become like family to her. Dr. Yamaguchi is highly rated in 22 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Intraductal Papilloma, Lymphadenectomy, and Mastectomy.

Expertise in
5
conditions
Dr. Mari A. Mori
Medical Genetics | Pediatrics
Expertise in
5
conditions
Dr. Mari A. Mori
Medical Genetics | Pediatrics
2201 Henderson Mill Rd Ne, Suite 160 C/o Esession, 
Atlanta, GA 
 (4.6 miles away)
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients

Mari Mori is a Medical Genetics specialist and a Pediatrics provider in Atlanta, Georgia. Dr. Mori is highly rated in 5 conditions, according to our data. Her top areas of expertise are FG Syndrome, Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Von Gierke Disease, and Ornithine Transcarbamylase Deficiency. Dr. Mori is currently accepting new patients.

Frequently Asked Questions about Dr. William Wilcox

How do I make an appointment with Dr. William Wilcox?

You can book an appointment with Dr. William Wilcox by calling their office at 404-778-8570. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William Wilcox a top-rated expert for Fabry Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William Wilcox is classified as an Elite expert for Fabry Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William Wilcox specialize in?

While Dr. William Wilcox is a Medical Genetics, they have specific expertise in Fabry Disease, Achondroplasia, and Mucopolysaccharidoses (MPS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Medical Genetics.

Does Dr. William Wilcox participate in research or clinical trials?

Yes. Dr. William Wilcox has published 62 articles and abstracts on conditions like Fabry Disease. You can view a list of Dr. William Wilcox's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. William Wilcox accept my insurance?

Dr. William Wilcox accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 404-778-8570 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilcox's expertise for a condition
ConditionClose
View All 24 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile